TXG News and Press, 10x Genomics Inc. From 05/13/22

Biotech is one of the fastest growing areas in healthcare, and one of the more exciting sectors in the stock market. Here's why three Fool.com contributors are bullish on 10x Genomics (NASDAQ: TXG) , Axsome Therapeutics (NASDAQ: AXSM) , and Doximity (NYSE: DOCS) ...

The release of Shockwave C² is a similar event to TAVRs for Edwards Lifesciences. Considering the cardiovascular industry tailwinds, the unique niche in calcified stenosis, and safety profile should allow a similar growth trajectory for SWAV. A tremendous earnings report...

10x Genomics (NASDAQ:TXG -8.1%) stock falls after the company on Wednesday posted wider Q1 net loss due to rise in costs.  Net loss for the quarter was $42.4M as compared to a net loss of $11.6M, a year ago. GAAP EPS of -$0.38, missed estimates by $0.07. Revenue grew 8% Y/Y to $114....

10x Genomics, Inc. (TXG) Q1 2022 Earnings Conference Call May 04, 2022 04:30 PM ET Company Participants Cassie Corneau - Investor Relations and Strategic Finance Serge Saxonov - Chief Executive Officer & Co-founder Justin McAnear - Chief Financial Officer Conference Call Participants Teja...

10x Genomics press release (NASDAQ:TXG): Q1 GAAP EPS of -$0.38 misses by $0.07. Revenue of $114.5M (+8.2% Y/Y) beats by $1.17M. 10x Genomics is maintaining its full year 2022 revenue guidance of $600 million to $630 million, representing 22% to 28% growth over full year 2021 revenue. For fu...

10x Genomics Reports First Quarter 2022 Financial Results PR Newswire Q1 2022 revenue growth of 8% over prior year PLEASANTON, Calif. , May 4, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the first qua...

10x Genomics to Present at the BofA Securities 2022 Healthcare Conference PR Newswire PLEASANTON, Calif. , April 26, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today ...

Cathie Wood's flagship actively managed ARK Innovation ETF (NYSEARCA:ARKK) tumbled on Thursday, falling by 5%. In fact, the fund saw 35 of its 36 holdings trade to the downside. The lone stock in the ARKK fund to end higher was the EV giant Tesla (TSLA), which posted a 3.2% ...

It's always reassuring when your audience loves your product. And for investors in 10x Genomics (NASDAQ: TXG) , that rings especially true. While Wall Street has been busy punishing the stock , which is down over 50% year to date, the total number of publications has skyrocketed...

10x Genomics Launches Two New Products to Unlock Wider Range of Samples for Single Cell Analysis on Chromium PR Newswire Fixed RNA Profiling Kit stabilizes human samples at collection; Nuclei Isolation Kit simplifies frozen sample analysis PLEASANTON, Calif. ...